Insider Selling: Tempus AI (NASDAQ:TEM) Director Sells $147,015.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer Doudna sold 2,673 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $147,015.00. Following the completion of the sale, the director directly owned 25,942 shares in the company, valued at approximately $1,426,810. This trade represents a 9.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

TEM stock opened at $58.31 on Tuesday. The stock has a market capitalization of $10.47 billion, a price-to-earnings ratio of -33.90 and a beta of 3.64. The firm’s 50-day moving average price is $50.14 and its two-hundred day moving average price is $54.80. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. Tempus AI’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.24) earnings per share. As a group, equities analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on TEM. Morgan Stanley dropped their price objective on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Guggenheim decreased their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Jefferies Financial Group began coverage on Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. Wolfe Research started coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $80.00 price target on shares of Tempus AI in a report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.54.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. Royal Bank of Canada boosted its position in Tempus AI by 201.2% during the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after acquiring an additional 17,359 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Tempus AI during the 1st quarter worth approximately $116,000. Prudential Financial Inc. bought a new position in shares of Tempus AI in the 2nd quarter worth approximately $276,000. Russell Investments Group Ltd. raised its position in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock valued at $13,446,000 after purchasing an additional 204,629 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.